Update on NCI in vitro drug screen utilities

Area of Science:

• Oncology
• Pharmacology
• Bioinformatics

Background:

• Anti-cancer drug development is expensive and challenging.
• The National Cancer Institute's (NCI) Developmental Therapeutics Program (DTP) offers preclinical screening services to aid this process.
• DTP has amassed extensive data on compound screening and molecular entity expression in human tumor cell lines.

Purpose of the Study:

• To describe the services and data resources provided by the Developmental Therapeutics Program (DTP).
• To highlight the accessibility of DTP's preclinical screening data for cancer research.
• To inform researchers about DTP's expanded screening capabilities and molecular target assays.

Main Methods:

• Screening of tens of thousands of compounds against a panel of 60 human tumor cell lines.
• Accumulation and public dissemination of molecular entity expression data for the 60 cell line panel.
• Conducting focused screens, including yeast mutant screens and NCI Diversity Set assays for molecular targets.

Main Results:

• Extensive databases of compound screening results and molecular profiles are publicly available.
• DTP has screened approximately 100,000 compounds against yeast mutants.
• Screening of the NCI Diversity Set has yielded data on effects against molecular targets.

Conclusions:

• The DTP provides valuable preclinical data resources to facilitate anti-cancer drug discovery.
• Publicly accessible data on cell line screening and molecular targets can accelerate therapeutic development.
• DTP's comprehensive services support researchers in identifying and developing novel cancer therapeutics.